The Comfort of Development, the Reality of Commercialization

Reflecting on several conversations we had over the past week with (prospective) clients surfaced an interesting dynamic. It is often very comfortable to remain in a research and development mode and do just one more study or one more round of product improvement, rather than pushing to achieve first device clearance and enable real commercial use.

This behavior is understandable. Moving into a commercial phase means that a product is no longer used only under controlled study conditions. New issues will emerge and the focus shifts from positive feedback and interest to actual adoption and revenue. Instead of discussing whether a product addresses an unmet need, you now need to demonstrate that it does so in practice and that customers are willing to pay for it.

Yet this is also where the real value is created. Seeing a product used in real-world settings, impacting real patients, is ultimately why all the effort was worthwhile.

For management teams, recognizing this dynamic is important when deciding on next steps. There are often valid reasons to conduct another study or further improve a product, but these decisions also affect time to market. The trade-offs are often more visible in startups, where runway and funding milestones force difficult choices. In corporates, innovation timelines are typically longer and resources are less directly tied to the success of a single project, making it easier to remain in development mode.

This difference is particularly important for leaders transitioning from a corporate environment into a startup. Making the right call requires judgment, careful consideration, and a clear understanding of what information is still needed—and what is simply postponing market validation.

Below we discuss a number of fictional cases. Any resemblance to actual people or organizations is incidental.

Case I – Medisense Instruments and WoundWatch™

Medisense Instruments had built a solid, if somewhat unexciting, business supplying hospital-grade sensors and monitoring hardware. The company was respected for its engineering capabilities and had enjoyed years of steady growth, but management wanted to create a more differentiated product.

After several years of development, the innovation team launched WoundWatch™, a wearable sensor system designed to continuously monitor wound healing by measuring parameters such as temperature, moisture, and tissue perfusion. The technology attracted considerable attention, but once deployed in clinical practice it became clear that the hardware itself was only part of the solution. Hospitals were already collecting vast amounts of patient data, and clinicians did not need another stream of measurements—they needed help turning data into decisions.

Real-world use quickly revealed two challenges. First, the product experienced the typical issues that only emerge outside controlled testing environments. Second, and more importantly, customer feedback consistently highlighted that the real value would come from software that could interpret the data, identify patients at risk, integrate into existing workflows, and generate actionable recommendations. While the hardware was necessary, it was not sufficient.

This created a difficult situation for the company because software development, analytics, clinical workflow design, and systems integration were far removed from its traditional strengths. The market was effectively telling Medisense that its next source of value would come from capabilities it did not yet possess.

Faced with this reality, the development team proposed a new multi-year program to build an even more advanced sensor platform to improve data quality and robustness. On paper, the proposal appeared well justified. Better sensors, additional measurements, and an expanded technology platform would improve trust in the data. Yet it also had an important side effect: it allowed the organization to remain in a familiar R&D mode for another four years without confronting the much harder commercial question of whether hospitals would actually pay for the broader solution customers were asking for.

The challenge for leadership was therefore not primarily a technology decision but a strategic one. Should the company invest years refining a component that customers already viewed as good enough, or should it engage directly with the market, develop new capabilities and partnerships, and further test whether the envisioned software-enabled solution could create real commercial value?

We worked with the management team to explore the different options and challenge the organization to quickly integrate lessons from the initial market feedback, continuously improving the offering in close collaboration with early users.

Case II – SureSeal™ Advanced Surgical Stapler

StapleNova Medical is a venture-backed startup developing SureSeal™, a next-generation surgical stapler for gastrointestinal procedures. In a market dominated by well-established products, SureSeal promises a meaningful improvement: a more uniform staple line and enhanced tissue compression technology intended to reduce the risk of post-operative leaks and complications.

From a regulatory perspective, the initial path to market is relatively straightforward. Bench testing and usability studies can demonstrate that the stapler performs its intended function safely and effectively. Early clinical studies can further confirm procedural success and short-term performance. However, these data alone are unlikely to convince surgeons, hospitals, or payers to pay a premium over existing alternatives.

The real commercial opportunity lies in demonstrating improved patient outcomes. Can SureSeal reduce anastomotic leak rates? Can it lower reoperation rates, shorten hospital stays, or reduce post-operative complications? Answering these questions requires large, carefully designed clinical studies with sufficient follow-up and robust endpoints. These studies are costly and time-consuming, making it critical to invest in them at the right moment.

To help navigate this challenge, we conducted a structured review of the clinical evidence landscape. By systematically evaluating published studies, we identified the gold-standard endpoints, trial designs, patient populations, and follow-up periods used to establish superiority in this category. The exercise provided a clear picture of what constitutes compelling evidence in the eyes of regulators, clinicians, and hospital decision-makers.

The company is led by a seasoned executive who spent many years in major corporates and clearly understands the importance of generating the right clinical evidence to enable market success. For the team, conducting these extensive studies seemed both logical and interesting. Since such evidence will eventually be required for commercial success, it appeared sensible to work out the studies in detail and start identifying clinical partners capable of executing them. For the clinical team, this is a comfortable environment, and progress can be measured through valuable discussions and interactions with KOLs.

However, from a business development perspective, it is less clear whether spending significant effort and management attention on these activities is the best use of resources at this early stage. These studies are expensive, and the currently available funding will not be sufficient to execute all of them. StapleNova Medical’s management will therefore need to set clear priorities.

Achieving initial regulatory clearance is invaluable for attracting additional funding. It significantly reduces regulatory and technical risk while opening the door to new investors.

One approach is to develop a claim roadmap: a sequence of evidence-generating studies that progressively build confidence in the technology. By linking each clinical study to a specific claim and strategic objective, SureSeal can build a coherent body of evidence over time—reducing risk, preserving capital, and ensuring that each study creates value on the path toward the strongest and most commercially meaningful claims.

Such a claim roadmap also supports communication with potential investors and, later, strategic partners. It can be used both internally and externally to communicate progress, priorities, and the overall development strategy.

Conclusion

The contrast with another client we supported last year in finalizing their CE submission is striking. As discussed in a previous post, the company was facing a rapidly disappearing runway, and we helped them secure their initial device clearance as quickly as possible through an aggressive regulatory strategy that maximized the available clinical evidence.

They did obtain clearance (in record time) and are now delivering products to their first commercial customers while preparing additional follow-up studies. The team is seeing the device being used on real patients by new physicians. This not only demonstrates that the device works and adds value in clinical practice, but also generates an enormous amount of useful feedback.

In the end, startups typically do not have the luxury of dreaming too big for too long. Milestone-based funding forces difficult choices. Securing initial market clearance quickly is often critical, and teams need to stay focused on that objective.

Sometimes, when working with first-time startup CEOs who have a strong corporate background, we need to help them make that transition and ensure there is an appropriate sense of urgency and focus. Yes, you need to dream big, and you are selling that dream. But you also need to make sure that you are taking meaningful steps with the funding you have available today. This requires exploring the proposition taking into consideration all the different facets to come to informed choices.

Erik 02

Erik van Dijk

Managing Partner

Don’t hesitate to ask us your questions.

Drop an e-mail or contact us via LinkedIn

This website uses cookies to ensure you get the best experience on our website. If you want to get more information about this, please view our privacy policy page.